Valuation: Glenmark Pharmaceuticals Limited

Market Cap 637B 6.7B 5.82B 5.43B 4.98B 9.43B 9.53B 63.97B 25.01B 319B 25.17B 24.62B 1,056B P/E 2026
44.2x
P/E 2027 * 27.2x
Enterprise Value 598B 6.29B 5.46B 5.09B 4.68B 8.85B 8.94B 60.02B 23.46B 299B 23.62B 23.1B 991B EV / Sales 2026
3.51x
EV / Sales 2027 * 3.71x
Free-Float
51.04%
Yield 2026
0.12%
Yield 2027 * 0.17%
1 day+1.31%
1 week+2.89%
Current month+0.66%
1 month+1.73%
3 months-6.04%
6 months+14.81%
Current year+10.42%
1 week 2,163
Extreme 2163
2,269.35
1 month 2,163
Extreme 2163
2,326
Current year 1,842.8
Extreme 1842.8
2,471.05
1 year 1,794
Extreme 1794
2,471.05
3 years 702.05
Extreme 702.05
2,471.05
5 years 348.9
Extreme 348.9
2,471.05
10 years 168
Extreme 168
2,471.05
Manager TitleAgeSince
Chief Executive Officer 56 1999-12-31
Director of Finance/CFO 54 2025-05-26
President - 2023-09-14
Director TitleAgeSince
Director/Board Member 58 -
Chairman 56 2011-05-11
Director/Board Member 85 2009-08-13
Change 5-day change 1-year change 3-year change Capi.($)
+1.31%+2.89% - - 6.6B
-1.22%-1.86%+18.18%+70.33% 49.54B
-1.75%+3.69%+60.31%+127.28% 40.07B
-0.08%+0.98%-3.72%+20.59% 12.4B
-0.79%+1.99%+16.92%+72.54% 11.85B
+1.72%-0.76%+31.31%+133.18% 9.1B
+1.34%+3.59%+15.87%+34.07% 6.94B
-0.26%-4.80%+39.24%-14.13% 6.88B
+0.79%+4.47%-31.29%+15.81% 5.63B
-2.49%+2.85%+30.39%+96.77% 4.63B
Average -0.15%+1.48%+19.69%+61.83% 16.34B
Weighted average by Cap. -0.76%+0.99%+27.89%+78.81%

Financials

2026 2027 *
Net sales 153B 1.61B 1.4B 1.3B 1.2B 2.26B 2.29B 15.36B 6.01B 76.54B 6.04B 5.91B 254B 168B 1.77B 1.53B 1.43B 1.31B 2.48B 2.51B 16.86B 6.59B 83.98B 6.63B 6.49B 278B
Net income 20.53B 216M 187M 175M 161M 304M 307M 2.06B 805M 10.26B 811M 793M 34.01B 23.34B 245M 213M 199M 183M 345M 349M 2.34B 916M 11.67B 922M 901M 38.66B
Net Debt -39.29B -413M -359M -334M -307M -581M -587M -3.94B -1.54B -19.64B -1.55B -1.52B -65.08B -14.47B -152M -132M -123M -113M -214M -216M -1.45B -568M -7.23B -571M -559M -23.97B
Logo Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
Employees
15,800
Date Price Change Volume
26-08-05 2,248.00 +1.31% 16,578
26-08-04 ₹2,219.00 +1.85% 15,032
26-08-03 ₹2,178.60 -2.45% 42,768
26-07-31 ₹2,233.30 +1.93% 22,582
26-07-30 ₹2,191.05 -3.13% 15,794
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
2,225.00INR
Average target price
2,501.36INR
Spread / Average Target
+12.42%

Quarterly revenue - Rate of surprise